Background: Up until recently, cervical cytology was the mainstay for cervical cancer screening. However, the established association between human papillomavirus (HPV) infection and cervical cancer has led to changes in preventive strategies, with cytology being replaced by the use of high-risk HPV (hrHPV) testing and primary prevention being achieved by HPV vaccination. In this context, the role of cervical cytology is shifting to secondary triage of HPV-positive women. As vaccination is leading to decreased HPV infections and significant cervical abnormalities (CIN2+), data on the impact of HPV vaccination on cervical cytology metrics, including positive predictive value (PPV) and negative predictive value (NPV), are starting to emerge. Summary: This is a review of updates in cervical cancer screening, including the use of primary HPV testing and the impact of HPV vaccination on cytology as part of cervical cancer screening. Key Messages: Cervical cancer screening and prevention are undergoing significant changes as there is widespread implementation of HPV vaccination and hrHPV testing is becoming the entry point for secondary prevention. Optimal screening approaches and intervals in this setting are currently being analyzed including the use of cytology and other ancillary techniques for triage of positive cases, as well as the effect of vaccination on the PPV and NPV of cytology in the detection of CIN2+.

Journal Section:
Gynecologic Cytopathology
Keywords:
Cervical cancer, Cancer screening, Human papillomavirus, Human papillomavirus vaccination, Positive predictive value, Negative predictive value
1.
Roe CJ, Hanley KZ. Updates in cervical cytology. Surg Pathol. 2018;11:589–99.
2.
Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening working Group. Br J Cancer. 1996;73:1001–5.
3.
Barroeta JE, Reilly ME, Steinhoff MM, Lawrence WD. Utility of the ThinPrep Imaging SystemR in the detection of squamous intraepithelial abnormalities on retrospective evaluation: can we trust the imager? Diagn Cytopathol. 2012;40(2):124–7.
4.
zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol. 1977;78:1–30.
5.
Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87(11):796–802.
6.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.
7.
Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing. Viruses. 2018;10(12):729.
8.
Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2005;23:2388–94.
9.
Von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015;1:22–31.
10.
Elfström KM, Smelov V, Johansson ALV, Eklund C, Naucler P, Arnheim-Dahlström L, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomized controlled trial. BMJ. 2014;348:g130.
11.
Rijkaart DC, Berkhof J, Rozendaal L, van Kemede FJ, Bulkmans NWJ, Heideman DAM, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomized controlled trial. Lancet Oncol. 2012;13(1):78–88.
12.
Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a randomized trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13(51):1–150.
13.
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dala Palma P, Del Mistro A, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl cancer Inst. 2008;100(7):492–501.
14.
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomized controlled trials. Lancet. 2014;383:524–32.
15.
Ronco G, Segnan N, Giorgi-Rossi P, Zappa P, Casadei GP, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006;98(11):765–74.
16.
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomized controlled trial. Lancet Oncol. 2010;11(3):249–57.
17.
Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189–97.
18.
Gottschlich A, Gondara L, Smith LW, Cook D, Martin RE, Lee M, et al. Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV for Cervical Cancer (HPV FOCAL) trial. Int J Cancer. 2022; 151(6):897–905.
19.
Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, et al. Comparison of HPV-16 and HPV-18 genotyping and cytological testing as triage testing within human papillomavirus-based screening in Mexico. JAMA Netw Open. 2019;2(11):e1915781.
20.
Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomized study within organized screening programme. BMJ. 2010;340:c1804.
21.
Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Buduckh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385–94.
22.
Syrjänen S, Shabalova IP, Petrovichev N, Kozachenko VP, Zakharova T, Pajanidi J, et al. Human papillomavirus testing and conventional PAP smear cytology as optional screening tools of women at different risk for cervical cancer in countries of Former Soviet Union. J Lower Genital Tract Dis. 2002;6:97–110. https://doi.org/10.1097/00128360-200204000-00006.
23.
Longatto-Filho A, Maeda MYS, Eržen M, Branca M, Roteli-Martins C, Naus P, et al. Conventional PAP smear and liquid-based cytology as screening tools in low-resource settings of Latin America. Experience of the Latin American Screening Study. Acta Cytol. 2005;49:500–6.
24.
Gilham C, Sargent A, Kitchener HC, Peto J. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RTC. Health Technol Assess. 2019;23(28):1–44.
25.
Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189–97. https://doi.org/10.1016/j.ygyno.2014.11.076.
26.
Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 or younger had previously been offered HPV vaccination: results of the Compass Pilot Randomized Trial. PLoS Med. 2017 19;14(9):e1002388.
27.
Borgfeldt C, Leksell A, Forslund O. Co-testing in cervical screening among 40-to 42-year-old women is unreasonable. Acta Obstet Gynecol Scand. 2022;101:374–8 Available from:
28.
Angioli R, Lopez S, Aloisi A, Terranova C, De Cicco C, Scaletta G, et al. Ten years of HPV vaccines: state of art and controversies. Crit Rev Oncol Hematol. 2016;102:65–72.
29.
Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomized, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99.
30.
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.
31.
Patel C, Brotherton JMI, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018;23(41):1700737.
32.
Ross J, Greaves J, Saville M, Earls P, Pagliuso J. Performance measures for Australian laboratories reporting cervical cytology 2009-2017: the impact of the national HPV vaccination program. Pathol. 2020;52(5):522–8.
33.
Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, et al. Prevalence of cervical disease at age 20 after immunization with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019;365:|1161.
34.
Falcaro M, Castañón A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. The effects of the National HPV Vaccination Programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a Register-based observational study. Lancet. 2021;398:2084–92.
35.
Kann H, Hortlund M, Eklund C, Dillner J, Faust H. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: population-based nested case-control study. Int J Cancer. 2020;146:2539–46.
36.
Hu S-Y, Kreimer AR, Porras C, Guillén D, Alfaro M, Darragh TM, et al. Performance of cervical screening a decade following HPV vaccination: the Costa Rica Vaccine Trial. J Natl Cancer Inst. 2022;114(9):djac107. https://doi.org/10.1093/jnci/djac107.
37.
CDC. Weekly Aug 24, 2018/67(33);909–17.
38.
Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowits LE. Human papillomavirus vaccine impact and effectiveness through 12 years after vaccine introduction in the United States, 2003 to 2018. Ann Int Med. 2022Jul;175(7):918–26.
39.
Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlée F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res. 2009;40:478–85.
40.
Wright TC, Stoler MH, Aslam S, Behrens CM. Knowledge of patients’ human papillomavirus status at the time of cytologic review significantly affects the performance of cervical cytology in the ATHENA study. Am J Clin Pathol. 2016;146:391–8.
41.
Brotherton JM, Fridman CL, May G, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377:2085–92.
42.
Thamsborg LH, Napolitano G, Larsen LG, Lynge E. Impact of HPV vaccination on outcome of cervical cytology screening in Denmark: a Register-based cohort study. Int J Cancer. 2018;143:1662–70.
43.
Sultana F, Winch K, Saville M, Brotherton JM. Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination? Int J Cancer. 2019;144(12): 2964–71.
44.
Hestbech MS, Lynge E, Kragstrup J, Siersma V, Vazquez-Prada Baillet M, Brodersen J. The impact of HPV vaccination on future cervical screening: a simulation study of two birth cohorts in Denmark. BMJ Open. 2015;5:e007921.
45.
Lei J, Ploner A, Lehtinen M, Sparén P, Dillner J, Elfström KM. Impact of HPV vaccination on cervical screening performance: a population-based cohort study. Br J Cancer. 2020;123(1):155–60.
46.
Palmer TJ, McFadden M, Pollock KGJ, Kavanagh K, Cuschieri K, Cruickshank M, et al. HPV immunisation and cervical screening – confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study. Br J Cancer. 2016;114:582–9.
47.
Teoh D, Nam G, Aase DA, Russell R, Melton GB, Kulasingam S, et al. Test performance of cervical cytology among adults with vs without human papillomavirus vaccination. JAMA Network Open. 2022;5(5):e2214020.
48.
Wright TC, Parvu V, Stoler MH, Kodsi S, Eckert K, Yanson K, et al. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: results from the baseline phase of the Onclarity Trial. Gynecol Oncol. 2019;153:259–65.
49.
Rossi PG, Carozzi F, Federici A, Ronco G, Zappa M, Franceschi S. Cervical cancer screening in women vaccinated against human papillomavirus infection: recommendations from a consensus conference. Prev Med. 2017;98:21–30.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.